Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  12/19/2015
Clinical Research Facility
mi
from
Hampton, VA
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 12/19/2015
Clinical Research Facility
mi
from
Hampton, VA
Click here to add this to my saved trials
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  12/19/2015
Clinical Research Facility
mi
from
Mechanicsville, VA
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 12/19/2015
Clinical Research Facility
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  12/19/2015
Clinical Research Facility
mi
from
Norfolk, VA
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 12/19/2015
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  12/19/2015
Clinical Research Facility
mi
from
Bluefield, WV
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 12/19/2015
Clinical Research Facility
mi
from
Bluefield, WV
Click here to add this to my saved trials
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  12/19/2015
Clinical Research Facility
mi
from
Cudahy, CA
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 12/19/2015
Clinical Research Facility
mi
from
Cudahy, CA
Click here to add this to my saved trials
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  12/19/2015
Clinical Research Facility
mi
from
Bethlehem, PA
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 12/19/2015
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  12/19/2015
mi
from
Liverpool,
20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 12/19/2015
mi
from
Liverpool,
Click here to add this to my saved trials
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Denver, CO
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Miami, FL
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
San Antonio, TX
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  12/21/2015
mi
from
Grafton,
Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 12/21/2015
mi
from
Grafton,
Click here to add this to my saved trials
A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Status: Enrolling
Updated:  12/24/2015
Winthrop University Hospital
mi
from
Mineola, NY
A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Status: Enrolling
Updated: 12/24/2015
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?
Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?
Status: Enrolling
Updated:  1/4/2016
Jewish Hospital
mi
from
Cincinnati, OH
Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?
Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?
Status: Enrolling
Updated: 1/4/2016
Jewish Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
Gut Microbiota of Renal Patients
Status: Enrolling
Updated:  1/4/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
Gut Microbiota of Renal Patients
Status: Enrolling
Updated: 1/4/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Callowhill DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Callowhill DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
City Line DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
City Line DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Cottman DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Cottman DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Franklin DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Franklin DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Market Street DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Market Street DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
PDI Walnut Tower DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
PDI Walnut Tower DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Philadelphia 42nd Street DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Philadelphia 42nd Street DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Philadelphia PMC-Lombard DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Philadelphia PMC-Lombard DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
South Broad Street
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
South Broad Street
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
South Philadelphia DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
South Philadelphia DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
University City DaVita
mi
from
Philadelphia, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
University City DaVita
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Radnor DaVita
mi
from
Radnor, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Radnor DaVita
mi
from
Radnor, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Abington DaVita
mi
from
Willow Grove, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Abington DaVita
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Willow Grove DaVita
mi
from
Willow Grove, PA
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Willow Grove DaVita
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated:  1/5/2016
Lourdes-Camden
mi
from
Camden, NJ
Choice Sets for Advance Directives
A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives
Status: Enrolling
Updated: 1/5/2016
Lourdes-Camden
mi
from
Camden, NJ
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.74.01144 Boehringer Ingelheim Investigational Site
mi
from
North Hollywood, CA
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.74.01144 Boehringer Ingelheim Investigational Site
mi
from
North Hollywood, CA
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
205.452.01153 Boehringer Ingelheim Investigational Site
mi
from
Evansville, IN
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
205.452.01153 Boehringer Ingelheim Investigational Site
mi
from
Evansville, IN
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.64.10004 Boehringer Ingelheim Investigational Site
mi
from
Flint, MI
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.64.10004 Boehringer Ingelheim Investigational Site
mi
from
Flint, MI
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1245.25.10008 Boehringer Ingelheim Investigational Site
mi
from
Jackson, MS
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1245.25.10008 Boehringer Ingelheim Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.75.038 Boehringer Ingelheim Investigational Site
mi
from
Asheboro, NC
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.75.038 Boehringer Ingelheim Investigational Site
mi
from
Asheboro, NC
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1160.129.32833 Boehringer Ingelheim Investigational Site
mi
from
Fargo, ND
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1160.129.32833 Boehringer Ingelheim Investigational Site
mi
from
Fargo, ND
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.89.11004 Boehringer Ingelheim Investigational Site
mi
from
Edmonton,
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.89.11004 Boehringer Ingelheim Investigational Site
mi
from
Edmonton,
Click here to add this to my saved trials
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
Status: Enrolling
Updated:  1/7/2016
Clinical Research Facility
mi
from
Huntsville, AL
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
Status: Enrolling
Updated: 1/7/2016
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
Status: Enrolling
Updated:  1/7/2016
Clinical Research Facility
mi
from
Mobile, AL
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
Status: Enrolling
Updated: 1/7/2016
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
Status: Enrolling
Updated:  1/7/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
Status: Enrolling
Updated: 1/7/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials